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Abstract 1 
Nucleotides are key subunits for nucleic acids and provide energy for intracellular metabolism. 2 
They can also be released from cells to act physiologically as extracellular messengers or 3 
pathologically as danger signals. Extracellular nucleotides stimulate membrane receptors in the 4 
P2 and P1 family. P2X are ATP-activated cation channels; P2Y and P1 are G-protein coupled 5 
receptors activated by ATP, ADP, UTP and UDP or adenosine, respectively. Renal P2 receptors 6 
influence both vascular contractility and tubular function. Renal cells also express 7 
ectonucleotidases that rapidly hydrolyze extracellular nucleotides. These enzymes integrate this 8 
multi-receptor purinergic-signaling complex by determining the nucleotide milieu, as well as 9 
titrating receptor activation. 10 
Purinergic signaling also regulates immune cell function by modulating the synthesis and release 11 
of various cytokines such as IL1-β and IL-18 as part of inflammasome activation. Abnormal or 12 
excessive stimulation of this intricate paracrine system can be pro- or anti-inflammatory, and is 13 
also linked to necrosis and apoptosis. Kidney tissue injury causes a localized increase in ATP 14 
concentration, and sustained activation of P2 receptors can lead to renal glomerular, tubular  15 
and vascular cell damage. Purinergic receptors also regulate the activity and proliferation of 16 
fibroblasts, promoting both inflammation and fibrosis in chronic disease. 17 
In this short review we summarize some of the recent findings related to purinergic signaling in 18 
the kidney. We focus predominantly on the P2X7 receptor, discussing why antagonists have so 19 
far disappointed in clinical trials and how advances in our understanding of purinergic signaling 20 
might help to reposition these compounds as potential treatments for renal disease. 21 
 3 
Introduction 22 
Since their discovery in the 1970s, P2 purinergic receptors (P2R) have evolved from an initially 23 
contentious biological concept 1, through to a progressive understanding of their complex 24 
physiological actions, emerging now as attractive and ‘druggable’ targets for disease 2, 3. To date, 25 
the most advanced potential therapeutic P2R targets are antagonists for P2Y12R to inhibit 26 
thrombosis 4, and P2X7R for the treatment of chronic inflammatory diseases such as 27 
rheumatoid arthritis 5 and COPD 6. Several P2X7R antagonists have completed Phase 2 clinical 28 
trials, but despite pre-clinical promise, these compounds have failed to deliver the expected 29 
benefit and so interest in P2X7R has declined. In this concise review we cover purinergic 30 
signaling in the kidney and explore the contribution of this system to renal physiology and 31 
disease. The main focus is on the role of P2X receptors , particularly P2X7R, in renal injury and 32 
disease. P2X7R can orchestrate interactions between the immune and vascular systems, and 33 
defining this complex interaction as inflammation and injury develop may help us unlock the 34 
potential of P2X7R antagonists as renal therapeutics.  35 
 36 
P2 receptors and purinergic signaling in the kidney 37 
Purinergic receptors are sub-classified as P1R that bind adenosine and P2R that are activated by 38 
purine/pyrimidine nucleotides; P2R are in turn subdivided into P2YR and P2XR. The 8 P2YRs are 39 
coupled to G-proteins and are activated with differing selectivity by adenosine triphosphate 40 
(ATP), adenosine diphosphate (ADP), uridine triphosphate (UTP) and uridine diphosphate (UDP). 41 
The 7 P2XRs are trimeric ligand-gated ion channels activated by ATP, but not, or only weakly, by 42 
ADP or adenosine monophosphate (AMP). The molecular properties of these receptors and 43 
their ligands are described in detail in the IUPHAR/BPS Guide to Pharmacology: 44 
http://www.guidetopharmacology.org. 45 
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P2 receptors are expressed in all segments of the nephron and renal cells often express multiple 46 
receptor subtypes at both the apical and basolateral cell membranes 7, 8. Renal cells can also 47 
release ATP and UTP into the extracellular space. This release is likely to be regulated and is 48 
facilitated by several transport systems that involve vesicular or lysosomal exocytosis , or 49 
channel-mediated release via connexins 9 or pannexins 10. Extracellular ATP and UTP have short 50 
half-lives due to rapid catabolism by ectonucleotidases (Figure 1) that are also expressed by 51 
renal cells 11, 12. Their immediate breakdown products, ADP and UDP, are potent agonists at 52 
P2Y1R,12R,13R, and P2Y6R,14R, respectively. Further metabolism of ADP produces the 5’AMP 53 
(through CD39) and eventually adenosine (through CD73), the agonist at P1R (A1,2A,2B,3) that 54 
are also present in renal epithelia. Thus, the kidney has complex and regulated machinery for 55 
hierarchical purinergic signaling integrated by the action of ectonucleotidases. Ascribing specific 56 
physiological functions to a given receptor subtype has been challenging: avai lable receptor 57 
agonists are not sufficiently selective and are often unstable 11. In contrast, selective and 58 
specific receptor antagonists are providing a pharmacological means of assessing the function(s) 59 
of this system in vivo. 60 
Extracellular nucleotides can influence a range of physiological functions, from cell -proliferation 61 
and growth, through to energy metabolism and transepithelial solute flux. These functions have 62 
been reviewed in depth recently 13 and we can provide only a brief overview. It is evident that 63 
abnormal P2R activity can occur in various inflammatory and non-inflammatory disease states 64 
ranging from hypertension 14 to transplant rejection, to polycystic kidney disease 15. However, 65 
more beguiling is the therapeutic potential for P2XR antagonists in chronic kidney disease (CKD).   66 
 67 
 68 
 69 
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P2 receptors control renal vascular and microvascular function 70 
P2 receptors are expressed throughout the vasculature and microvasculature (Figure 2) and 71 
strongly influence vessel function 16. The renal vasculature and microvasculature also expresses 72 
NTPDase1 (CD39) that hydrolyses ATP to ADP and AMP, and thereby rapidly curtail purinergic 73 
signaling 17. P2X1R is the dominant receptor in vascular smooth muscle and application of ATP 74 
to the adventitia evokes contraction in the pre-glomerular vasculature 18, 19. P2X1R null mice 75 
display an attenuated pressure-induced constriction of the afferent arteriole 20 and targeted 76 
deletion of NTPDase1 prolongs the half-life of extracellular ATP, enhancing the vascular 77 
response to increased pressure 21. 78 
Direct renal artery infusion of ATP increases blood flow, causing vasodilation due to production 79 
of nitric oxide (NO) by the endothelium 22 and also NO-independent vasodilatation induced by 80 
intra-renal prostanoids 23. The P2 receptor subtype(s) that mediates the vasodilatatory response 81 
to ATP is unknown. In human arterial endothelial cells and endothelial cells cultured from the 82 
mouse pulmonary artery, P2X4R is the most abundantly expressed receptor, followed by P2X7R 83 
24-26. P2X4R mediates the release of NO in response to increased shear stress 24. This response is 84 
lost in P2X4R null mice, which have endothelial dysfunction and hypertension 25. P2X7R 85 
activation seems to promote a tonic vasoconstriction of both the pre-glomerular arteries and 86 
medullary microcirculation 14, which is discussed more below. Other P2 receptors can influence 87 
endothelial function, for example, vasodilatation caused by UDP is abolished in P2Y6R null mice 88 
27. The descending vasa recta are also affected by extracellular nucleotides, since infusion of 89 
ATP into the renal artery reduces medullary blood flow as a result of P2X1R activation 23, and 90 
ATP released from sympathetic nerves causes constriction of vasa recta pericytes 28.  91 
 92 
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Multiple P2R subtypes are expressed in glomerular cells (Figure 2). Under normal conditions, 93 
P2YR predominate 29 and extracellular nucleotides influence mesangial proliferation and 94 
contraction, as well as contraction of the parietal sheet 29. In podocytes, P2Y1R is the dominant 95 
functional receptor as demonstrated by comprehensive pharmacological profiling and 96 
immunolocalization 30; however, recently P2X4R has been shown to have a mechano-sensitive 97 
role affecting the podocyte actin cytoskeleton 31, although P2X4R knockout mice, while 98 
hypertensive, have no obvious gross glomerular phenotype and are not known to be proteinuric. 99 
In contrast, P2Y1R null mice are protected from acute nephrotoxic injury, showing preserved 100 
renal function, reduced capillary rarefaction and fibrosis, and enhanced survival 32. P2Y1R 101 
activation may, therefore, contribute to glomerular injury. P2X7R expression also seems to be 102 
associated with glomerular injury, since it is increased in multiple glomerular cells types, 103 
including inflammatory cells, in models of severe hypertension, type 1 diabetes 33, and acute 104 
inflammatory glomerulonephritis 34. Uncovering the primary role of this increased glomerular 105 
P2X7R expression remains an active area of research. 106 
 107 
P2 receptors and renal tubular physiology 108 
P2R exert a largely inhibitory effect on tubular electrolyte transport and this, together with 109 
expression in specific nephron segments, has been reviewed extensively elsewhere 35 and is 110 
summarized in Figure 2. The processes are best defined for sodium flux, which is tonically 111 
suppressed by P2R activation in several nephron segments  36. It is likely that such paracrine 112 
control by extracellular nucleotides provides a route for rapid modulation of tubular transport 113 
that can link solute and fluid delivery to adaptive transport capacity, for example adenosine-114 
mediated tubuloglomerular feedback is impaired in CD73-/- mice 37. This form of control can 115 
integrate with more slowly adapting hormonal systems, for example the renin-angiotensin-116 
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aldosterone system (RAAS) to regulate the phenomenon of aldosterone escape 38. Indeed, ATP 117 
release by tubular cells, stimulated by increased flow, contributes to the control of extracellular 118 
fluid volume by the kidney, and blood pressure regulation, as discussed below.  119 
 120 
Proximal tubule  121 
The proximal tubule, which expresses apical P2Y1R and P2X5R, and basolateral P2Y4R and 122 
P2Y6R 39, 40, accounts for reabsorption of ~65% of the filtered sodium load. Extracellular 123 
nucleotides inhibit the major sodium transporters in this segment, NHE3 41, NaPi2 42 and Na,K-124 
ATPase 43, and inhibition of transepithelial flux has been confirmed in vivo 44. The ATP 125 
concentration in tubular fluid is unknown, although measurements in bulk fluid collected from 126 
the end of the proximal convoluted tubule (PCT) report concentrations of 100-300nmol/l 45. The 127 
brush border membrane expresses ENPP3 (ectonucleotide pyrophosphatase/ phospodiesterase 128 
3) and ecto-5’-nucleotidase (NT5E; CD73) 12 that should terminate physiological signaling. 129 
Microperfusion studies using nucleotide scavengers suggest that the ‘ambient’ concentration of 130 
the physiological purinergic ligand, most probably ADP, is ~10mol/l, exerting a tonic inhibitory 131 
effect that may help to balance tubular sodium reabsorption with glomerular filtration 44. 132 
 133 
The distal nephron 134 
Increased fluid flow or changes in osmolality of the tubular fluid promotes nucleotide secretion 135 
in both the thick limb of Henle 46 and collecting duct 47, inhibiting transport in downstream 136 
nephron segments. In the thick ascending limb of Henle (TALH), ATP release is dependent on 137 
activation of the transient receptor potential cation channel TRPV4 osmosensor 48. These 138 
nucleotides activate endothelial NO synthase (NOS3) in thick limb cells, and P2R signaling 139 
underpins the flow-dependent increase in NO production 49 and subsequent inhibition of apical 140 
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NKCC2 and basolateral Na,K-ATPase activity 50. Studies in knockout mice suggest P2X4R and 141 
P2Y2R contribute to this signaling arc 51, 52.  142 
Extracellular ATP has long been known to inhibit the epithelial sodium channel (ENaC), the rate-143 
limiting step for sodium transport in the connecting tubule and collecting duct 53. Studies in 144 
isolated segments show that ATP activates P2Y2R to reduce the open probability of ENaC 54-56. 145 
P2yr2 null mice lack the tonic suppression of ENaC and are hypertensive 54. Studies in vivo 146 
suggest that P2X4R activation also inhibits ENaC 53, 57 and our own pilot studies in a P2X4R null 147 
mouse suggest that this receptor may be important in the modulation of sodium transport by 148 
aldosterone (Craigie et al, unpublished).  149 
 150 
P2R and blood pressure regulation 151 
Hypertension is a major modifiable risk factor for cardiovascular and renal disease and is highly 152 
prevalent 58. Human genetic studies have found an association between SNPs in P2XR encoding 153 
genes and blood pressure or cardiovascular disease. The loss of function variant rs28360472 in 154 
P2RX4 associates with increased pulse pressure 59, itself an important cardiovascular risk factor. 155 
An intronic SNP (rs591874) in the gene encoding P2X7R is associated with elevated blood 156 
pressure 60. The loss of function variant rs3751143 is common (25% heterozygosity and up to 3% 157 
homozygosity) and protects against ischemic stroke 61. The physiology of P2RX7 genetic 158 
variation is almost certainly subtle, if not complex. For example, rs3751143 does not associate 159 
with impaired endothelial dysfunction or vascular stiffness in essential hypertensives 62, but 160 
does confer a significantly reduced sensitivity to P2X7R antagonism 63. 161 
Pressure-natriuresis is an important mechanism of long-term blood pressure control 64 and is 162 
modulated by paracrine factors that inhibit sodium transport in the renal proximal tubule, 163 
including extracellular nucleotides. Microdialysis experiments reveal a direct relationship 164 
between renal artery perfusion pressure and the concentration of ATP in the interstitial fluid of 165 
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the kidney cortex 65. As mentioned earlier, extracellular nucleotides inhibit the key transporters 166 
in the proximal tubule 41-43. This natriuretic effect is buttressed by inhibition of sodium transport 167 
in the distal nephron. Increased flow through the collecting duct promotes ATP secretion to 168 
inhibit ENaC. This ATP release is abolished in connexin 30 knockout mice, severely attenuating 169 
the pressure-natriuresis response 9. Consistent with this, mice over-expressing human 170 
NTPDase1 (CD39), a cell surface enzyme that scavenges extracellular nucleotides, display a small 171 
impairment of the natriuretic response to a high sodium diet and concomitant aldosterone 172 
infusion 66. It is assumed that P2Y2R mediates the inhibitory effect of ATP on distal tubule 173 
sodium transport. Receptor agonists have been considered as potential antihypertensives. 174 
P2yr2 null mice display enhanced ENaC activity and are hypertensive. Surprisingly, blood 175 
pressure is salt resistant 67 and endothelial dysfunction with impaired NO release may be causal. 176 
Recent studies also suggest that ATP can inhibit ENaC indirectly: in IMCD cells, activation of 177 
P2X7R promotes synthesis of endothelin-1, which is pro-natriuretic due to ETB-mediated 178 
inhibition of ENaC 68.  However, the significance of this cell line-based study is not clear, since 179 
acute P2X7R antagonism in vivo improves the pressure-natriuresis relationship 14. 180 
Although P2X7R activation contributes to the physiological control of blood pressure by the 181 
kidney, sustained activation of the receptor, which does not de-sensitize with repeated 182 
exposure to ATP, promotes hypertensive renal injury. Thus, prophylactic P2X7R antagonism 69 or 183 
‘knock-out’ of the murine P2X7k transcript 70, which leaves several functional P2RX7 transcripts 184 
intact 71, protects against the injury associated with salt-sensitive hypertension. P2X7R 185 
antagonism/deletion reduced albuminuria and interstitial fibrosis, lowered blood pressure and 186 
reduced the infiltration of T and B cells, macrophages and leucocytes. The mechanisms 187 
underpinning these effects are not known, as discussed further below. Our data suggest that 188 
P2X7R in the renal vasculature and microvasculature may impair blood pressure regulation by 189 
the kidney 14. We identified elevated renal expression of P2X7R (and P2X4R) as a candidate gene 190 
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for hypertensive renal vascular injury in rats 72. P2X7R localized to the vascular and 191 
microvascular endothelium down to afferent arterioles. The selective P2X7R antagonist 192 
AZ11657312 increased renal medullary perfusion and improved tissue oxygenation in 193 
angiotensin II–treated rats 14; these beneficial effects were partially dependent on NO synthesis. 194 
Overall, activation of P2X7R induces microvascular dysfunction and regional hypoxia, 195 
particularly under high angiotensin II tone. These effects are pro-inflammatory and may 196 
contribute to progression of renal injury. In the next section, we discuss the role of P2X7R in 197 
renal injury and disease and assess the potential for antagonists as renal therapeutics.  198 
 199 
P2XR and renal injury 200 
There is consistent pre-clinical evidence supporting a role for P2X7R in inflammation (Figure 3), 201 
and, as already mentioned, P2X7R antagonists have been explored as a treatment target in 202 
rheumatoid arthritis 5, COPD 6, and IBD 73, but with mixed or generally disappointing results. This 203 
has caused interest in the receptor to wax and wane. However, it is likely that an improved 204 
understanding of the biological roles of P2X7R, including its unique two-stage ability to induce 205 
membrane permeability to large (>900 Da) molecules, rather than cations alone, as well as the 206 
regulation and function of the main splice variants, will provide a fresh impetus to the clinical 207 
testing of antagonists. 208 
In the normal kidney P2X7R is typically only present at low levels, often undetectable by RNA 209 
analysis in whole kidney extracts. The receptor is normally localized to certain compartments, 210 
particularly the vasculature and microvasculature, at least in the rat 7, 14, 72. A wealth of data 211 
shows that injury/inflammation increases expression in renal cells. For example, TNFα can 212 
induce expression of P2X7R in cultured mesangial cells  74. In renal biopsy material from patients 213 
with lupus nephritis, increased expression of P2X7R protein has been found 75. Nevertheless, it 214 
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remains to be investigated whether the extent of P2X7R expression correlates with the severity 215 
of clinical disease and a more detailed study with larger patient numbers is needed.  216 
 217 
Glomerulonephritis 218 
A more detailed characterization of the expression and potential function of P2X7R have been 219 
carried out in rodent models of nephrotoxic nephritis (NTN) 75. In a mouse model of accelerated 220 
NTN, increased expression of P2X7R was co-localized to glomerular macrophages as well as 221 
intrinsic glomerular cells. In NTN in WKY rats, onset P2X7R expression coincided with onset of 222 
proteinuria. The inflamed glomeruli are infiltrated by macrophages showing the NLRP3 223 
inflammasome activation 76. The WKY strain of rat is known to be more susceptible to 224 
developing severe and progressive glomerulonephritis when compared with the resistant LEW 225 
rat strain. WKY and LEW rats have identical MHC genes, but have distinct genetic differences 226 
and differences in their expression of P2X7R and the NLRP3 inflammasome 76. More specifically, 227 
bone marrow derived (BMD) macrophages from WKY rats have increased expression of P2X7R 228 
protein and mRNA associated with increased expression of multiple genes of the NLRP3 229 
inflammasome pathway, even in their basal state in vitro, again when compared with BMD 230 
macrophages from LEW rats. Following priming with endotoxin and stimulation with 231 
extracellular ATP, compared with LEW rats, macrophages from WKY rats have higher levels of 232 
caspase-1 activation and secretion of more mature IL-1β and IL-18. Thus, strain differences in 233 
expression of P2X7R and subsequent downstream activation of the inflammasome may be 234 
responsible for the difference in susceptibility to experimental glomerulonephritis. 235 
The functional importance of P2X7R was investigated in gene knockout mice and with systemic 236 
treatment by a small molecule P2X7R antagonist 34. Using the model of accelerated NTN, the 237 
P2X7R knockout mice had lower urinary monocyte chemoattract-1 (CCL2), fewer infiltrating 238 
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glomerular macrophages, less glomerular fibrin deposition and less proteinuria than in wild-type 239 
mice. In NTN rats, treatment with the P2X7R antagonist A438079 significantly reduced 240 
glomerular expression of CCL2, glomerular macrophage infiltration, glomerular fibrinoid 241 
necrosis and proteinuria compared with vehicle-treated rats. However, exactly how P2X7R is 242 
involved in antibody-mediated glomerulonephritis is unclear. Typically, extracellular ATP binds 243 
to P2X7R in endotoxin-primed macrophages, resulting in inflammasome activation and release 244 
of mature IL-1βand IL-18 77, yet endotoxin or other bacterial products are not involved in the 245 
induction of NTN in WKY rats 34. The interaction between immune complex stimulation and 246 
P2X7R needs further investigation and to ascertain whether treatment with the P2X7R 247 
antagonist after the onset of disease is effective in reducing the severity of glomerulonephritis. 248 
There is also recent evidence in lupus prone mice that treatment with a P2X7R antagonist can 249 
decrease the severity of renal injury and levels of dsDNA antibodies  78.  250 
 251 
Acute kidney injury 252 
Renal ischemia-reperfusion injury (IRI) is a common occurrence in many clinical settings from 253 
sepsis to major surgery, including renal transplantation. There is increased expression of P2X7R, 254 
mainly in the renal tubules, in a mouse model of renal IRI; treatment with A438079 reduced 255 
renal expression of chemokines (MCP-1 and RANTES), p-ERK, NGAL, renal tubular injury and cell 256 
death 79. 257 
As well as the mentioned increase in P2X7R in a rat model of type 1 diabetes 33, in a mouse 258 
model of high fat diet-induced metabolic disease, proteinuria and albuminuria developed in the 259 
wild-type mice, but not in P2X7a variant knockout mice 80. In the high fat diet fed mice there 260 
was also increased renal expression of P2X7R and components of the NLRP3 inflammasome that 261 
were attenuated in the high fat diet fed P2X7R knockout mice, as was renal expression of 262 
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chemokine CCL2, macrophage infiltration and expression of extracellular matrix protein. 263 
Moreover, increased expression of P2X7R and inflammasome components were found in renal 264 
tissue from patients with glomerulonephritis 75. 265 
 266 
Fibrosis  267 
Purinergic signaling is involved in tissue remodeling (Figure 3) and several studies in various 268 
tissues suggest that these pathways may also drive tissue fibrosis in chronic injury, one feature 269 
of which is a sustained increase in ambient concentrations of ATP, ADP, UTP and UDP 81. Tissue 270 
fibroblasts express multiple P2R subtypes and respond to extracellular nucleotides by activating 271 
key pathways for the production of extracellular matrix. In cardiac fibroblasts, for example, 272 
P2Y2R activation is strongly pro-fibrotic 82, and activation of P2X4R and P2X7R promotes 273 
ERK1/2-dependent fibroblast proliferation 83. This cluster of P2Rs is also relevant to the kidney 274 
in which fibroblasts and mesangial cells mainly determine ECM deposition. In this context, 275 
P2Y2R activation increases mesangial cell proliferation 74 and P2X7R activation increases matrix 276 
production by mesangial cells 84. 277 
The role of P2 receptors in renal fibrosis has been investigated in the unilateral ureteral 278 
obstruction (UUO) model 85. Transient expression of P2X7R was detected only in tubular 279 
epithelial cells 7 days after induction of UUO in wild-type mice. The renal tubular expression of 280 
TGF-β1, macrophage infiltration, tubular apoptosis and tubulointerstitial fibrosis were reduced 281 
in P2X7R knockout mice compared with wild-type mice by day 14. The role of the 282 
inflammasome in this model has also been investigated. Knockout of apoptosis-associated 283 
speck-like protein containing a caspase recruitment domain (ASC) in mice results in reduced 284 
UUO-mediated tubulointerstitial fibrosis, together with fewer infiltrating inflammatory cells and 285 
reduced renal expression of mRNA for IL-1β, CCL2, TGFβ1 and collagen I; however, it is not clear 286 
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how P2X7R may regulate TGF-β1 expression 86. While there is a well-established relationship 287 
between stimulation of P2X7R and activation of the inflammasome, it is not known what the 288 
priming signal is in the sterile UUO model and what triggers fibrogenesis.  289 
P2X4R is closely related to P2X7R and there has been ongoing controversy over whether P2X4R 290 
and P2X7R can form heterotrimers 87, 88. The potential importance of P2X4R in renal fibrosis has 291 
been investigated in the UUO model. Surprisingly, the P2X4R knockout mice showed increased 292 
renal fibrosis following induction of UUO associated with increased expression of TGFβ1 and 293 
connective tissue growth factor (CTGF, also known as CCN2), and increased amounts of type I 294 
collagen 89. These results suggest that P2X7R is pro-fibrotic in this model and that P2X4R may 295 
have an anti-fibrotic role through its regulation of pro-fibrotic growth factors. 296 
More recent studies show that nucleotidases may also contribute to fibrosis by regulating the 297 
half-life of ATP. ENTPD1 (CD39)-null mice are more sensitive to ischemic tissue injury than wild-298 
type mice 90, because ATP persists and its hydrolysis to protective adenosine is blunted.  299 
Similarly, these null mice have more pronounced renal injury in the IRI model 91, 92; although in 300 
this setting the role of adenosine is less certain, since the deletion of CD73, the enzyme that 301 
converts AMP to adenosine, was also protective 93. Overall, these data suggest that enzymes 302 
involved in terminating P2R signaling may be less tractable as therapeutic targets than the 303 
receptors themselves. Recent studies indicate that CD39 expression by T-reg lymphocytes is 304 
essential for their pro-reparative role in response to chronic renal injury 94. 305 
 306 
What now for P2X7R antagonists? 307 
P2X7R antagonists may have failed because of significant gaps in our knowledge about the 308 
complex processing and diverse roles of P2XR7 gene products and the implications this may 309 
have for P2X7R in disease. Single nucleotide polymorphisms (SNPs) such as rs3751143 (causing 310 
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Glu496Ala) can impair P2X7R function 95, 96: ATP-dependent IL-1 release from lymphocytes is 311 
significantly suppressed in individuals carrying this SNP 97. Alternative splicing can produce novel 312 
protein isoforms that are emerging as important factors in disease pathogenesis, as well as in 313 
determining the right treatment target 98.  314 
Human P2X7R has at least 10 splice isoforms, the functions of which have not been unraveled; 315 
however, in rodents, the common ‘k variant’ of P2X7R is much more sensitive to ATP than the 316 
original full-length ‘a variant’ 99. Pre-clinical data suggest that genetic variation in P2X7R will 317 
increase the population wide variance of both agonist and antagonist binding affinities, 318 
suggesting that we need to re-evaluate or redefine clinical trials on the basis of the P2X7R 319 
“fingerprint”. The tissue distribution, regulation and function of these splice isoforms in the 320 
healthy kidney is just beginning to be explored; the pharmacogenomics of P2X7R and the impact 321 
of disease is largely unknown. The next phase of research will define these key biological 322 
processes involving P2X7R, which may not all be ‘bad’ 100, and provide a better understanding of 323 
how isoform-specific receptor antagonists should be deployed in kidney disease. Is this P2X7R 324 
Redux? 325 
  326 
 16 
References: 327 
1. Burnstock G. Purinergic nerves. Pharmacol Rev 1972; 24: 509-581. 328 
 329 
2. Burnstock G. Introduction: P2 receptors. Curr Top Med Chem 2004; 4: 793-803. 330 
 331 
3. Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic 332 
Signal 2008; 4: 1-20. 333 
 334 
4. van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible 335 
direct P2Y12 antagonists. Semin Thromb Hemost 2005; 31: 195-204. 336 
 337 
5. Keystone EC, Wang MM, Layton M, et al. Clinical evaluation of the efficacy of the P2X7 338 
purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid 339 
arthritis in patients with active disease despite treatment with methotrexate or 340 
sulphasalazine. Ann Rheum Dis 2012; 71: 1630-1635. 341 
 342 
6. Eltom S, Stevenson CS, Rastrick J, et al. P2X7 receptor and caspase 1 activation are 343 
central to airway inflammation observed after exposure to tobacco smoke. PLoS One 344 
2011; 6: e24097. 345 
 346 
7. Menzies RI, Unwin RJ, Bailey MA. Renal P2 receptors and hypertension. Acta Physiol 347 
(Oxf) 2015; 213: 232-241. 348 
 349 
8. Bailey MA, Hillman KA, Unwin RJ. P2 receptors in the kidney. J Auton Nerv Syst 2000; 81: 350 
264-270. 351 
 352 
9. Sipos A, Vargas SL, Toma I, et al. Connexin 30 deficiency impairs renal tubular ATP 353 
release and pressure natriuresis. J Am Soc Nephrol 2009; 20: 1724-1732. 354 
 355 
10. Jackson MF. Interdependence of ATP signalling and pannexin channels; the servant was 356 
really the master all along? Biochem J 2015; 472: e27-30. 357 
 358 
11. Shirley DG, Vekaria RM, Sevigny J. Ectonucleotidases in the kidney. Purinergic Signal 359 
2009; 5: 501-511. 360 
 361 
12. Vekaria RM, Shirley DG, Sevigny J, et al. Immunolocalization of ectonucleotidases along 362 
the rat nephron. Am J Physiol Renal Physiol 2006; 290: F550-560. 363 
 364 
13. Burnstock G. Purinergic signalling: from discovery to current developments. Exp Physiol 365 
2014; 99: 16-34. 366 
 367 
14. Menzies RI, Howarth AR, Unwin RJ, et al. Inhibition of the purinergic P2X7 receptor 368 
improves renal perfusion in angiotensin-II-infused rats. Kidney Int 2015; 88: 1079-1087. 369 
 370 
15. Hillman KA, Woolf AS, Johnson TM, et al. The P2X7 ATP receptor modulates renal cyst 371 
development in vitro. Biochem Biophys Res Commun 2004; 322: 434-439. 372 
 373 
 17 
16. Inscho EW. ATP, P2 receptors and the renal microcirculation. Purinergic Signal 2009; 5: 374 
447-460. 375 
 376 
17. Zhang Y, Morris KL, Sparrow SK, et al. Defective renal water handling in transgenic mice 377 
over-expressing human CD39/NTPDase1. Am J Physiol Renal Physiol 2012; 303: F420-430.  378 
 379 
18. Chan CM, Unwin RJ, Bardini M, et al. Localization of P2X1 purinoceptors by 380 
autoradiography and immunohistochemistry in rat kidneys. Am J Physiol 1998; 274: 381 
F799-804. 382 
 383 
19. Inscho EW, Cook AK, Imig JD, et al. Physiological role for P2X1 receptors in renal 384 
microvascular autoregulatory behavior. J Clin Invest 2003; 112: 1895-1905. 385 
 386 
20. Inscho EW, Cook AK, Imig JD, et al. Renal autoregulation in P2X1 knockout mice. Acta 387 
Physiol Scand 2004; 181: 445-453. 388 
 389 
21. Kauffenstein G, Drouin A, Thorin-Trescases N, et al. NTPDase1 (CD39) controls 390 
nucleotide-dependent vasoconstriction in mouse. Cardiovasc Res 2010; 85: 204-213. 391 
 392 
22. Eltze M, Ullrich B. Characterization of vascular P2 purinoceptors in the rat isolated 393 
perfused kidney. Eur J Pharmacol 1996; 306: 139-152. 394 
 395 
23. Eppel GA, Ventura S, Evans RG. Regional vascular responses to ATP and ATP analogues in 396 
the rabbit kidney in vivo: roles for adenosine receptors and prostanoids. Br J Pharmacol 397 
2006; 149: 523-531. 398 
 399 
24. Yamamoto K, Korenaga R, Kamiya A, et al. P2X(4) receptors mediate ATP-induced 400 
calcium influx in human vascular endothelial cells. Am J Physiol Heart Circ Physiol 2000; 401 
279: H285-292. 402 
 403 
25. Yamamoto K, Sokabe T, Matsumoto T, et al. Impaired flow-dependent control of vascular 404 
tone and remodeling in P2X4-deficient mice. Nat Med 2006; 12: 133-137. 405 
 406 
26. Ray FR, Huang W, Slater M, et al. Purinergic receptor distribution in endothelial cells in 407 
blood vessels: a basis for selection of coronary artery grafts. Atherosclerosis 2002; 162: 408 
55-61. 409 
 410 
27. Bar I, Guns PJ, Metallo J, et al. Knockout mice reveal a role for P2Y6 receptor in 411 
macrophages, endothelial cells, and vascular smooth muscle cells. Mol Pharmacol 2008; 412 
74: 777-784. 413 
 414 
28. Crawford C, Kennedy-Lydon TM, Callaghan H, et al. Extracellular nucleotides affect 415 
pericyte-mediated regulation of rat in situ vasa recta diameter. Acta Physiol (Oxf) 2011; 416 
202: 241-251. 417 
 418 
29. Bailey MA, Turner CM, Hus-Citharel A, et al. P2Y receptors present in the native and 419 
isolated rat glomerulus. Nephron Physiol 2004; 96: p79-90. 420 
 421 
 18 
30. Ilatovskaya DV, Palygin O, Levchenko V, et al. Pharmacological characterization of the P2 422 
receptors profile in the podocytes of the freshly isolated rat glomeruli. Am J Physiol Cell 423 
Physiol 2013; 305: C1050-1059. 424 
 425 
31. Forst AL, Olteanu VS, Mollet G, et al. Podocyte Purinergic P2X4 Channels Are 426 
Mechanotransducers That Mediate Cytoskeletal Disorganization. J Am Soc Nephrol 2016; 427 
27: 848-862. 428 
 429 
32. Hohenstein B, Renk S, Lang K, et al. P2Y1 gene deficiency protects from renal disease 430 
progression and capillary rarefaction during passive crescentic glomerulonephritis. J Am 431 
Soc Nephrol 2007; 18: 494-505. 432 
 433 
33. Vonend O, Turner CM, Chan CM, et al. Glomerular expression of the ATP-sensitive P2X 434 
receptor in diabetic and hypertensive rat models. Kidney Int 2004; 66: 157-166. 435 
 436 
34. Taylor SR, Turner CM, Elliott JI, et al. P2X7 deficiency attenuates renal injury in 437 
experimental glomerulonephritis. J Am Soc Nephrol 2009; 20: 1275-1281. 438 
 439 
35. Burnstock G, Evans LC, Bailey MA. Purinergic signalling in the kidney in health and 440 
disease. Purinergic Signal 2014; 10: 71-101. 441 
 442 
36. Praetorius HA, Leipziger J. Intrarenal purinergic signaling in the control of renal t ubular 443 
transport. Annu Rev Physiol 2010; 72: 377-393. 444 
 445 
37. Castrop H, Huang Y, Hashimoto S, et al. Impairment of tubuloglomerular feedback 446 
regulation of GFR in ecto-5'-nucleotidase/CD73-deficient mice. J Clin Invest 2004; 114: 447 
634-642. 448 
 449 
38. Stockand JD, Mironova E, Bugaj V, et al. Purinergic inhibition of ENaC produces 450 
aldosterone escape. J Am Soc Nephrol 2010; 21: 1903-1911. 451 
 452 
39. Bailey MA, Imbert-Teboul M, Turner C, et al. Evidence for basolateral P2Y(6) receptors 453 
along the rat proximal tubule: functional and molecular characterization. J Am Soc 454 
Nephrol 2001; 12: 1640-1647. 455 
 456 
40. Bailey MA, Shirley DG. Effects of extracellular nucleotides on renal tubular solute 457 
transport. Purinergic Signal 2009; 5: 473-480. 458 
 459 
41. Bagorda A, Guerra L, Di Sole F, et al. Extracellular Adenine Nucleotides Regulate Na+/H+ 460 
Exchanger NHE3 Activity in A6-NHE3 Transfectants by a cAMP/PKA-dependent 461 
Mechanism. J Membr Biol 2002; 188: 249-259. 462 
 463 
42. Lee YJ, Park SH, Jeung TO, et al. Effect of adenosine triphosphate on phosphate uptake in 464 
renal proximal tubule cells: involvement of PKC and p38 MAPK. J Cell Physiol 2005; 205: 465 
68-76. 466 
 467 
43. Jin W, Hopfer U. Purinergic-mediated inhibition of Na+-K+-ATPase in proximal tubule 468 
cells: elevated cytosolic Ca2+ is not required. Am J Physiol 1997; 272: C1169-1177. 469 
 470 
 19 
44. Bailey MA. Inhibition of bicarbonate reabsorption in the rat proximal tubule by 471 
activation of luminal P2Y1 receptors. Am J Physiol Renal Physiol 2004; 287: F789-796. 472 
 473 
45. Vekaria RM, Unwin RJ, Shirley DG. Intraluminal ATP concentrations in rat renal tubules. J 474 
Am Soc Nephrol 2006; 17: 1841-1847. 475 
 476 
46. Jensen ME, Odgaard E, Christensen MH, et al. Flow-induced [Ca2+]i increase depends on 477 
nucleotide release and subsequent purinergic signaling in the intact nephron. J Am Soc 478 
Nephrol 2007; 18: 2062-2070. 479 
 480 
47. Bjaelde RG, Arnadottir SS, Overgaard MT, et al. Renal epithelial cells can release ATP by 481 
vesicular fusion. Front Physiol 2013; 4: 238. 482 
 483 
48. Silva GB, Garvin JL. TRPV4 mediates hypotonicity-induced ATP release by the thick 484 
ascending limb. Am J Physiol Renal Physiol 2008; 295: F1090-1095. 485 
 486 
49. Silva G, Beierwaltes WH, Garvin JL. Extracellular ATP stimulates NO production in rat 487 
thick ascending limb. Hypertension 2006; 47: 563-567. 488 
 489 
50. Silva GB, Garvin JL. Extracellular ATP inhibits transport in medullary thick ascending 490 
limbs: role of P2X receptors. Am J Physiol Renal Physiol 2009; 297: F1168-1173. 491 
 492 
51. Marques RD, de Bruijn PI, Sorensen MV, et al. Basolateral P2X receptors mediate 493 
inhibition of NaCl transport in mouse medullary thick ascending limb (mTAL). Am J 494 
Physiol Renal Physiol 2012; 302: F487-494. 495 
 496 
52. Marques RD, Praetorius HA, Leipziger J. P2Y2 receptor knock-out mice display normal 497 
NaCl absorption in medullary thick ascending limb. Front Physiol 2013; 4: 280. 498 
 499 
53. Shirley DG, Bailey MA, Unwin RJ. In vivo stimulation of apical P2 receptors in collecting 500 
ducts: evidence for inhibition of sodium reabsorption. Am J Physiol Renal Physiol 2005. 501 
 502 
54. Pochynyuk O, Bugaj V, Rieg T, et al. Paracrine regulation of the epithelial Na+ channel in 503 
the mammalian collecting duct by purinergic P2Y2 receptor tone. J Biol Chem 2008; 283: 504 
36599-36607. 505 
 506 
55. Deetjen P, Thomas J, Lehrmann H, et al. The luminal P2Y receptor in the isolated 507 
perfused mouse cortical collecting duct. J Am Soc Nephrol 2000; 11: 1798-1806. 508 
 509 
56. Lehrmann H, Thomas J, Kim SJ, et al. Luminal P2Y2 receptor-mediated inhibition of Na+ 510 
absorption in isolated perfused mouse CCD. J Am Soc Nephrol 2002; 13: 10-18. 511 
 512 
57. Wildman SS, Marks J, Turner CM, et al. Sodium-dependent regulation of renal amiloride-513 
sensitive currents by apical P2 receptors. J Am Soc Nephrol 2008; 19: 731-742. 514 
 515 
58. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of 516 
worldwide data. Lancet 2005; 365: 217-223. 517 
 518 
 20 
59. Stokes L, Scurrah K, Ellis JA, et al. A loss-of-function polymorphism in the human P2X4 519 
receptor is associated with increased pulse pressure. Hypertension 2011; 58: 1086-1092. 520 
 521 
60. Palomino-Doza J, Rahman TJ, Avery PJ, et al. Ambulatory blood pressure is associated 522 
with polymorphic variation in P2X receptor genes. Hypertension 2008; 52: 980-985. 523 
 524 
61. Gidlof O, Smith JG, Melander O, et al. A common missense variant in the ATP receptor 525 
P2X7 is associated with reduced risk of cardiovascular events. PLoS One 2012; 7: e37491. 526 
 527 
62. Ghiadoni L, Rossi C, Duranti E, et al. P2X7 receptor polymorphisms do not influence 528 
endothelial function and vascular tone in neo-diagnosed, treatment-naive essential 529 
hypertensive patients. J Hypertens 2013; 31: 2362-2369. 530 
 531 
63. McHugh SM, Roman S, Davis B, et al. Effects of genetic variation in the P2RX7 gene on 532 
pharmacodynamics of a P2X(7) receptor antagonist: a prospective genotyping approach. 533 
Br J Clin Pharmacol 2012; 74: 376-380. 534 
 535 
64. Ivy JR, Bailey MA. Pressure natriuresis and the renal control of arterial blood pressure. J 536 
Physiol 2014; 592: 3955-3967. 537 
 538 
65. Nishiyama A, Majid DS, Taher KA, et al. Relation between renal interstitial ATP 539 
concentrations and autoregulation-mediated changes in renal vascular resistance. Circ 540 
Res 2000; 86: 656-662. 541 
 542 
66. Zhang Y, Robson SC, Morris KL, et al. Impaired natriuretic response to high-NaCl diet plus 543 
aldosterone infusion in mice overexpressing human CD39, an ectonucleotidase 544 
(NTPDase1). Am J Physiol Renal Physiol 2015; 308: F1398-1408. 545 
 546 
67. Rieg T, Bundey RA, Chen Y, et al. Mice lacking P2Y2 receptors have salt-resistant 547 
hypertension and facilitated renal Na+ and water reabsorption. FASEB J 2007. 548 
 549 
68. Pandit MM, Inscho EW, Zhang S, et al. Flow regulation of endothelin-1 production in the 550 
inner medullary collecting duct. Am J Physiol Renal Physiol 2015; 308: F541-552. 551 
 552 
69. Ji X, Naito Y, Hirokawa G, et al. P2X(7) receptor antagonism attenuates the hypertension 553 
and renal injury in Dahl salt-sensitive rats. Hypertens Res 2012; 35: 173-179. 554 
 555 
70. Ji X, Naito Y, Weng H, et al. P2X7 deficiency attenuates hypertension and renal injury in 556 
deoxycorticosterone acetate-salt hypertension. Am J Physiol Renal Physiol 2012; 303: 557 
F1207-1215. 558 
 559 
71. Masin M, Young C, Lim K, et al. Expression, assembly and function of novel C-terminal 560 
truncated variants of the mouse P2X7 receptor: re-evaluation of P2X7 knockouts. Br J 561 
Pharmacol 2012; 165: 978-993. 562 
 563 
72. Menzies RI, Unwin RJ, Dash RK, et al. Effect of P2X4 and P2X7 receptor antagonism on 564 
the pressure diuresis relationship in rats. Front Physiol 2013; 4: 305. 565 
 566 
 21 
73. Eser A, Colombel JF, Rutgeerts P, et al. Safety and Efficacy of an Oral Inhibitor of the 567 
Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's 568 
Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study. Inflamm 569 
Bowel Dis 2015; 21: 2247-2253. 570 
 571 
74. Harada H, Chan CM, Loesch A, et al. Induction of proliferation and apoptotic cell death 572 
via P2Y and P2X receptors, respectively, in rat glomerular mesangial cells. Kidney Int 573 
2000; 57: 949-958. 574 
 575 
75. Turner CM, Tam FW, Lai PC, et al. Increased expression of the pro-apoptotic ATP-576 
sensitive P2X7 receptor in experimental and human glomerulonephritis. Nephrol Dial 577 
Transplant 2007; 22: 386-395. 578 
 579 
76. Deplano S, Cook HT, Russell R, et al. P2X7 receptor-mediated Nlrp3-inflammasome 580 
activation is a genetic determinant of macrophage-dependent crescentic 581 
glomerulonephritis. J Leukoc Biol 2013; 93: 127-134. 582 
 583 
77. Ferrari D, Pizzirani C, Adinolfi E, et al. The P2X7 receptor: a key player in IL-1 processing 584 
and release. J Immunol 2006; 176: 3877-3883. 585 
 586 
78. Zhao J, Wang H, Dai C, et al. P2X7 blockade attenuates murine lupus nephritis by 587 
inhibiting activation of the NLRP3/ASC/caspase 1 pathway. Arthritis Rheum 2013; 65: 588 
3176-3185. 589 
 590 
79. Yan Y, Bai J, Zhou X, et al. P2X7 receptor inhibition protects against ischemic acute 591 
kidney injury in mice. Am J Physiol Cell Physiol 2015; 308: C463-472. 592 
 593 
80. Solini A, Menini S, Rossi C, et al. The purinergic 2X7 receptor participates in renal 594 
inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome 595 
activation. J Pathol 2013; 231: 342-353. 596 
 597 
81. Lu D, Insel PA. Cellular mechanisms of tissue fibrosis. 6. Purinergic signaling and response 598 
in fibroblasts and tissue fibrosis. Am J Physiol Cell Physiol 2014; 306: C779-788. 599 
 600 
82. Lu D, Insel PA. Hydrolysis of extracellular ATP by ectonucleoside triphosphate 601 
diphosphohydrolase (ENTPD) establishes the set point for fibrotic activity of cardiac 602 
fibroblasts. J Biol Chem 2013; 288: 19040-19049. 603 
 604 
83. Chen JB, Liu WJ, Che H, et al. Adenosine-5'-triphosphate up-regulates proliferation of 605 
human cardiac fibroblasts. Br J Pharmacol 2012; 166: 1140-1150. 606 
 607 
84. Solini A, Iacobini C, Ricci C, et al. Purinergic modulation of mesangial extracellular matrix 608 
production: role in diabetic and other glomerular diseases. Kidney Int 2005; 67: 875-885. 609 
 610 
85. Goncalves RG, Gabrich L, Rosario A, Jr., et al. The role of purinergic P2X7 receptors in the 611 
inflammation and fibrosis of unilateral ureteral obstruction in mice. Kidney Int 2006; 70: 612 
1599-1606. 613 
 614 
 22 
86. Komada T, Usui F, Shirasuna K, et al. ASC in renal collecting duct epithelial cells 615 
contributes to inflammation and injury after unilateral ureteral obs truction. Am J Pathol 616 
2014; 184: 1287-1298. 617 
 618 
87. Guo C, Masin M, Qureshi OS, et al. Evidence for functional P2X4/P2X7 heteromeric 619 
receptors. Mol Pharmacol 2007; 72: 1447-1456. 620 
 621 
88. Antonio LS, Stewart AP, Xu XJ, et al. P2X4 receptors interact with both P2X2 and P2X7 622 
receptors in the form of homotrimers. British Journal of Pharmacology 2011; 163: 1069-623 
1077. 624 
 625 
89. Kim MJ, Turner CM, Hewitt R, et al. Exaggerated renal fibrosis in P2X4 receptor-deficient 626 
mice following unilateral ureteric obstruction. Nephrol Dial Transplant 2014; 29: 1350-627 
1361. 628 
 629 
90. Kohler D, Eckle T, Faigle M, et al. CD39/ectonucleoside triphosphate diphosphohydrolase 630 
1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 631 
2007; 116: 1784-1794. 632 
 633 
91. Grenz A, Zhang H, Hermes M, et al. Contribution of E-NTPDase1 (CD39) to renal 634 
protection from ischemia-reperfusion injury. FASEB J 2007; 21: 2863-2873. 635 
 636 
92. Roberts V, Lu B, Rajakumar S, et al. The CD39-adenosinergic axis in the pathogenesis of 637 
renal ischemia-reperfusion injury. Purinergic Signal 2013; 9: 135-143. 638 
 639 
93. Rajakumar SV, Lu B, Crikis S, et al. Deficiency or inhibition of CD73 protects in mild 640 
kidney ischemia-reperfusion injury. Transplantation 2010; 90: 1260-1264. 641 
 642 
94. Wang YM, McRae JL, Robson SC, et al. Regulatory T cells participate in CD39-mediated 643 
protection from renal injury. Eur J Immunol 2012; 42: 2441-2451. 644 
 645 
95. Gu BJ, Zhang W, Worthington RA, et al. A Glu-496 to Ala polymorphism leads to loss of 646 
function of the human P2X7 receptor. J Biol Chem 2001; 276: 11135-11142. 647 
 648 
96. Sluyter R, Shemon AN, Wiley JS. Glu496 to Ala polymorphism in the P2X7 receptor 649 
impairs ATP-induced IL-1 beta release from human monocytes. J Immunol 2004; 172: 650 
3399-3405. 651 
 652 
97. Ali Z, Laurijssens B, Ostenfeld T, et al. Pharmacokinetic and pharmacodynamic profiling 653 
of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects. Br J Clin 654 
Pharmacol 2013; 75: 197-207. 655 
 656 
98. Stevens M, Oltean S. Alternative Splicing in CKD. J Am Soc Nephrol 2016; 27: 1596-1603. 657 
 658 
99. Bartlett R, Stokes L, Sluyter R. The P2X7 receptor channel: recent developments and the 659 
use of P2X7 antagonists in models of disease. Pharmacol Rev 2014; 66: 638-675. 660 
 661 
 23 
100.   de Torre-Minguela C, Barbera-Cremades M, Gomez AI, et al. Macrophage activation and 662 
polarization modify P2X7 receptor secretome influencing the inflammatory process. Sci 663 
Rep 2016; 6 :22586. 664 
 665 
 666 
  667 
 24 
Acknowledgements 668 
Research in the authors’ laboratories was funded by The British Heart Foundation and Kidney 669 
Research UK.  670 
Disclosures 671 
RJU is currently on secondment as Chief Scientist to Cardiovascular and Metabolic Diseases 672 
(iMed CVMD) R&D, AstraZeneca, Mölndal, Sweden. FWKT and MAB have received research 673 
funding from AstraZeneca.  674 
 675 
 676 
 677 
  678 
 25 
Figure 1: The autocrine / paracrine purinoceptor system 679 
A range of stimuli including cellular stretch, trauma, or agonist binding triggers ATP release into 680 
the extracellular space. Ectonucleotidases located on the plasma membrane catalyse sequential 681 
hydrolysis of ATP to ADP, 5’AMP and adenosine. P1 receptors recognize adenosine while P2 682 
receptors bind di- and tri-phosphate nucleotide molecules. P2X receptors are non-selective 683 
cation channels with 3 protein subunits that may form homo- or heteromeric arrangements; all 684 
bind ATP. P2Y receptors are 7 transmembrane-spanning domain G-protein-coupled receptors; 685 
agonist preferences span adenosine and uracil di- and tri- nucleotides. NTPDase: ectonucleoside 686 
triphosphate diphosphohydrolase. 687 
 688 
Figure 2: P2 Receptors in the kidney 689 
P2Y and P2X receptor expression along the nephron: vasculature, glomeruli and tubules. 690 
 691 
Figure 3: P2XR related inflammation in (diabetic) kidney disease 692 
Local production of chemokines, adhesion molecules and inflammatory cytokines are 693 
upregulated under chronic stimulation of factors including hyperglycemia. Macrophages are the 694 
main infiltrating inflammatory cell type (expressing P2X7R) in both the glomerular and 695 
tubulointerstitial compartments where they contribute to extracellular matrix (ECM) secretion, 696 
amplification of the inflammatory cascade and eventually fibrosis. 697 
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